British Columbia’s life sciences sector is a leader in the development of new products and therapies, particularly in the areas of clinical research and testing, medical devices, biopharmaceuticals, and food and drug processing technologies.
British Columbia’s life sciences sector enjoys international partnerships that open doors for exports. Organizations from around the world have seen opportunities for discoveries, pharmaceuticals and devices here in B.C. Opportunities exist for new partnerships with British Columbia’s key trading partners.
Europe is home to several industry leaders in the life sciences sector, including Merck and GlaxoSmithKline. Europe also has several prominent life sciences clusters throughout the continent, with Germany having the largest number of biotech and medtech companies and the United Kingdom having the largest pharmaceutical cluster.
Learn more about British Columbia’s export opportunities in Europe.
India is one of the world’s key life sciences markets.. Anchored by generic drug manufacturing, the industry has seen significant investment in research and development since it began recognizing product patents in 2005. The country’s pharmaceutical industry is expected to grow to $45 billion U.S. by 2020, while the biotech sector, rooted in research and development, was valued at $11 billion in 2016.
Learn more about British Columbia’s export opportunities in India.
Backed by strong government support, South Korea boasts a robust and growing R&D sector, particularly in biotech, with several innovative drugs receiving approval in recent years providing a dynamic opportunity for British Columbia life science companies.
Learn more about British Columbia’s export opportunities in South Korea.